Get the Stockscreener App
171.07
2.53%
-4.925
Insmed Inc stock is traded at $171.07, with a volume of 532.28K.
It is down -2.53% in the last 24 hours and down -12.72% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$176.00
Open:
$174.17
24h Volume:
532.28K
Relative Volume:
0.19
Market Cap:
$36.51B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-27.68
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
-1.44%
1M Performance:
-12.72%
6M Performance:
+78.43%
1Y Performance:
+161.02%
1-Day Range:
$170.47
$175.00
1-Week Range:
$167.39
$178.75
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
171.17 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.25 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
814.85 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
414.12 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.27 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” - Insider Monkey
How analysts rate Insmed Incorporated stock todayInterest Rate Changes & Affordable Trading Techniques - ulpravda.ru
Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - MarketScreener
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Market Review: Why Insmed Incorporated IM8N stock remains top ratedAnalyst Downgrade & High Conviction Investment Ideas - moha.gov.vn
Allspring Global Investments Holdings LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Calamos Advisors LLC Acquires 12,263 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insmed (FRA:IM8N) EV-to-OCF : -39.13 (As of Dec. 25, 2025) - GuruFocus
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Investors to Reach Out - ACCESS Newswire
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Insmed price target lowered to $230 from $240 at HC Wainwright - MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Pharmaceutical Stocks To ConsiderDecember 21st - MarketBeat
Why Insmed Incorporated stock is considered a top pickMarket Sentiment Extremes & Free Professional Investment Consultations - Bollywood Helpline
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insmed Inc (NASDAQ:INSM) Nasdaq Today Anchors Clinical Innovation - Kalkine Media
Insmed, Inc. (NASDAQ:INSM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open - ts2.tech
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025) - ts2.tech
Insmed Incorporated(NasdaqGS: INSM) added to NASDAQ-100 Index - marketscreener.com
What is HC Wainwright's Forecast for Insmed FY2025 Earnings? - MarketBeat
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):